We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.57 | 1.97% | 29.505 | 29.425 | 29.58 | 29.58 | 29.005 | 29.015 | 412,807 | 22:50:04 |
From Nov 2023 to May 2024
By Pierre Bertrand
Bayer said that its menopause drug Elinzanetant met the primary endpoints of its Oasis 1 and 2 Phase 3 studies.
When compared with placebo, the drug showed a statistically significant reduction in the frequency and the severity of moderate to severe vasomotor symptoms, also known as hot flashes.
It also demonstrated statistically significant improvements in sleep disturbances and menopause-related quality of life, the company said.
The Oasis 1 and 2 studies assessed the efficacy and safety of Elinzanetant when administered orally once daily. The result of the Oasis 3 Phase 3 study is expected in the coming months, Bayer said.
The company added that it plans to submit the data from the Oasis studies to health authorities for marketing authorizations.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
January 08, 2024 02:50 ET (07:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
